iTeos Therapeutics, Inc. is a pharmaceutical company based in the United States of America. With a medium risk rating score of 23.0, iTeos focuses on developing novel product candidates to enhance clinical outcomes by reinvigorating the immune response against cancer. ESG principles are at the core of iTeos' mission to design products with optimized pharmacologic properties. Their product pipeline includes EOS-850, an Adenosine A2A receptor-specific antagonist, EOS-448, an ADCC-enabled anti-TIGIT immune checkpoint blocking antibody, and other innovative drug candidates.